Pancreatic Cancer Research

ResearcherUniversity of MiamiActive in the last 2 years

Jason A. Castellanos

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-0771-3727; OpenAlex author ID A5108806413. Sources: OpenAlex.

Their work

Papers
10 (first author 5, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
16
Papers, trials and grants by year

2013: 1 paper · 2014: 1 paper · 2015: 1 paper · 2016: 1 paper · 2017: none · 2018: 2 papers · 2019: 2 papers · 2020: none · 2021: 1 paper · 2022: none · 2023: none · 2024: none · 2025: 1 paper

Papers 10

  1. Editor's Note: Inverse Correlation of STAT3 and MEK Signaling Mediates Resistance to RAS Pathway Inhibition in Pancreatic Cancer. First author DOI 10.1158/0008-5472.can-25-1304↗
  2. Combined Blockade of MEK and CDK4/6 Pathways Induces Senescence to Improve Survival in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1158/1535-7163.mct-19-1043↗
  3. Urolithin A, a Novel Natural Compound to Target PI3K/AKT/mTOR Pathway in Pancreatic Cancer. Co-author DOI 10.1158/1535-7163.mct-18-0464↗
  4. Src kinase inhibition restores E-cadherin expression in dasatinib-sensitive pancreatic cancer cells. Co-author DOI 10.18632/oncotarget.26621↗
  5. Tobacco Carcinogen-Induced Production of GM-CSF Activates CREB to Promote Pancreatic Cancer. Co-author DOI 10.1158/0008-5472.can-18-0579↗
  6. Inverse Correlation of STAT3 and MEK Signaling Mediates Resistance to RAS Pathway Inhibition in Pancreatic Cancer. First author DOI 10.1158/0008-5472.can-18-0634↗
  7. Optical Imaging of Drug-Induced Metabolism Changes in Murine and Human Pancreatic Cancer Organoids Reveals Heterogeneous Drug Response. First author DOI 10.1097/mpa.0000000000000543↗
  8. Signal Transducer and Activator of Transcription 3, Mediated Remodeling of the Tumor Microenvironment Results in Enhanced Tumor Drug Delivery in a Mouse Model … First author DOI 10.1053/j.gastro.2015.07.058↗
  9. Intensity of follow-up after pancreatic cancer resection. Co-author DOI 10.1245/s10434-013-3289-7↗
  10. Emerging targets in pancreatic cancer: epithelial-mesenchymal transition and cancer stem cells. First author DOI 10.2147/ott.s34670↗

Closest collaborators

The 16 strongest of 16 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Nipun B. Merchant · 9 shared papers, 2014–2025 · strength 0.91
  2. Nagaraj S. Nagathihalli · 9 shared papers, 2013–2025 · strength 0.88
  3. Michael Nathan VanSaun · 6 shared papers, 2018–2025 · strength 0.70
  4. Chanjuan Shi · 5 shared papers, 2015–2025 · strength 0.54
  5. Austin R. Dosch · 4 shared papers, 2018–2021 · strength 0.37
  6. Supriya Srinivasan · 3 shared papers, 2018–2021 · strength 0.27
  7. Xi Chen · 1 shared paper, 2025 · strength 0.25
  8. Tulasigeri M. Totiger · 2 shared papers, 2018–2019 · strength 0.15
  9. Brent A. Willobee · 1 shared paper, 2021 · strength 0.12
  10. Siddharth Mehra · 1 shared paper, 2021 · strength 0.12
  11. Melissa Caroline Skala · 2 shared papers, 2015–2016 · strength 0.12
  12. Alex J. Walsh · 2 shared papers, 2015–2016 · strength 0.12
  13. Xi Chen · 1 shared paper, 2019 · strength 0.08
  14. Kumaraswamy Malleshappa Honnenahally · 1 shared paper, 2018 · strength 0.07
  15. Merchant · 1 shared paper, 2013 · strength 0.06
  16. Harold L. Moses · 1 shared paper, 2015 · strength 0.05

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.